Lactobacillus acidophilus NCFM affects colonic mucosal opioid receptor expression in patients with functional abdominal pain - A randomised clinical study

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 2, 2014, Pages 200-207

  Ringel Kulka, T ^a   Goldsmith, J R ^a   Carroll, I M ^a   Barros, S P ^b   Palsson, O ^a   Jobin, C ^a,c   Ringel, Y ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 2 RECEPTOR; MESSENGER RNA; MU OPIATE RECEPTOR; OPIATE RECEPTOR; PROBIOTIC AGENT; STAT3 PROTEIN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COLON BIOPSY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LACTOBACILLUS ACIDOPHILUS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; STOMACH FUNCTION; SYNDROME DELINEATION; TREATMENT DURATION; YOUNG ADULT;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; COLON; DOUBLE-BLIND METHOD; ENTEROCYTES; FEMALE; HUMANS; INTESTINAL MUCOSA; LACTOBACILLUS ACIDOPHILUS; MIDDLE AGED; PROBIOTICS; RECEPTOR, CANNABINOID, CB2; RECEPTORS, OPIOID, MU; RNA, MESSENGER; STAT3 TRANSCRIPTION FACTOR; YOUNG ADULT;

EID: 84902833209     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12800     Document Type: Article

References (26)

1. Backhed F, Fraser CM, Ringel Y, et al,. Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications. Cell Host Microbe 2012; 12: 611-22.
2. Bibiloni R, Fedorak RN, Tannock GW, et al,. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005; 100: 1539-46.
3. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A,. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009; 104: 437-43.
4. Whelan K, Quigley EM,. Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr Opin Gastroenterol 2013; 29: 184-9.
5. Sartor RB,. Microbial Influences in Inflammatory Bowel Diseases. Gastroenterology 2008; 134: 577-94.
6. Saulnier DM, Ringel Y, Heyman MB, et al,. The intestinal microbiome, probiotics and prebiotics in neurogastroenterology. Gut Microbes 2013; 4: 17-27.
7. Ringel Y, Ringel-Kulka T,. The rationale and clinical effectiveness of probiotics in irritable bowel syndrome. J Clin Gastroenterol 2011; 45 (Suppl.): S145-8.
8. Ringel-Kulka T,. Targeting the intestinal microbiota in the pediatric population: a clinical perspective. Nutr Clin Pract 2012; 27: 226-34.
9. Ringel Y, Maharshak N,. Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2013; 305: G529-41.
10. Sanders ME, Klaenhammer TR,. Invited review: the scientific basis of Lactobacillus acidophilus NCFM functionality as a probiotic. J Dairy Sci 2001; 84: 319-31.
11. Petersen ER, Claesson MH, Schmidt EG, et al,. Consumption of probiotics increases the effect of regulatory T cells in transfer colitis. Inflamm Bowel Dis 2012; 18: 131-42.
12. Rousseaux C, Thuru X, Gelot A, et al,. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 2007; 13: 35-7.
13. Ringel-Kulka T, Palsson OS, Maier D, et al,. Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study. J Clin Gastroenterol 2011; 45: 518-25.
14. Goldsmith JR, Uronis JM, Jobin C,. Mu opioid signaling protects against acute murine intestinal injury in a manner involving Stat3 signaling. Am J Pathol 2011; 179: 673-83.
15. Philippe D, Chakass D, Thuru X, et al,. Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation. Gut 2006; 55: 815-23.
16. Uronis JM, Muhlbauer M, Herfarth HH, Rubinas TC, Jones GS, Jobin C,. Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS ONE 2009; 4: e6026.
17. Francis CY, Morris J, Whorwell PJ,. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997; 11: 395-402.
18. Law P-Y, Wong YH, Loh HH,. Molecular mechanisms and regulation of opioid receptor signaling. Annu Rev Pharmacol Toxicol 2000; 40: 389-430.
19. Pan Y-X,. Diversity and complexity of the mu opioid receptor gene: alternative pre-mRNA splicing and promoters. DNA Cell Biol 2005; 24: 736-50.
20. Bueno L, Fioramonti J,. Action of opiates on gastrointestinal function. Baillieres Clin Gastroenterol 1988; 2: 123-39.
21. Tillisch K, Labus J, Kilpatrick L, et al,. Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology 2013; 144: 1394-401, 1401.e1-4.
22. Holzer P,. Opioid antagonists for prevention and treatment of opioid-induced gastrointestinal effects. Curr Opin Anaesthesiol 2010; 23: 616-22.
23. Goldsmith JR, Cocchiaro JL, Rawls JF, Jobin C,. Glafenine-induced intestinal injury in zebrafish is ameliorated by mu-opioid signaling via enhancement of Atf6-dependent cellular stress responses. Dis Model Mech 2012; 6: 146-59.
24. Goldsmith JR, Perez-Chanona E, Yadav PN, Whistler J, Roth B, Jobin C,. Intestinal epithelial cell-derived mu-opioid signaling protects against ischemia reperfusion injury through PI3K signaling. Am J Pathol 2013; 182: 776-85.
25. Goldsmith JR, Kelly M, Freeman KB, Duro D,. Combined restitutive therapy for treatment of immunosuppressive refractory Crohn's disease. J Pediatr Gastroenterol Nutr 2013; PMID: 24121152 [Epub ahead of print].
26. Philippe D, Dubuquoy L, Groux H, et al,. Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation. J Clin Investig 2003; 111: 1329-38.